NYT reports good, bad, uglyHansen buys stake in cardiac therapy firm
Whether scans help or not, insurers pay, reports The New York Times, whose article March 2 illuminated a dark corner of the medical reimbursement world. As many as 20% to 50% of imaging procedures produce results that do not help diagnose ailments or treat patients, according to studies cited by the NYT. There can be many reasons. The paper noted that insurers pay the same for a scan done on a 10-year-old machine as for one on the latest model, "though the differences in the images can be significant." A policy change favoring more reimbursement for newer and better technology could mean a lot to manufacturers, but it's not likely to come any time soon. Among the cash-strapped community of hospitals and outpatient centers, old machines are likely to get older.
Hansen Medical is investing in Advanced Cardiac Therapeutics (ACT) by purchasing an equity stake that will secure the surgical robotics company exclusive rights to intellectual properties important for its interventional system. The technology at the center of this investment measures the temperature in cardiac lesions, which could prove critically important in monitoring the effect of Hansen's Sensei Robotic Catheter System, which assists cardiac ablation procedures by improving control over catheter movement in the heart. Hansen is banking on the potential of building this technology, called the Microwave Radiometry System, into its catheters. Although promising, ACT's technology has not yet been clinically tested or received regulatory approval.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study Explores Impact of Insurance on Treatment and Referrals for Patients with Uterine Fibroids
February 19th 2025Women with uterine fibroids and Medicaid coverage are significantly more likely to be treated with uterine artery embolization than those with commercial insurance, according to newly published research.